Protalix BioTherapeutics Inc.  

(Public, NYSEMKT:PLX)   Watch this stock  
Find more results for NYSEAMEX:PLX
1.95
-0.03 (-1.52%)
Dec 19 - Close
NYSEMKT real-time data - Disclaimer
Currency in USD
Range 1.92 - 1.99
52 week 1.86 - 5.30
Open 1.96
Vol / Avg. 0.00/297,977.00
Mkt cap 718.66M
P/E     -
Div/yield     -
EPS -1.37
Shares 93.67M
Beta 0.88
Inst. own 18%
Mar 12, 2015
Q4 2014 Protalix Biotherapeutics Inc Earnings Release (Estimated) Add to calendar
Nov 11, 2014
Q3 2014 Protalix Biotherapeutics Inc Earnings Release
Nov 10, 2014
Protalix Biotherapeutics Inc Annual Shareholders Meeting
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -216.08% -241.38%
Operating margin -167.47% -235.53%
EBITD margin - -213.47%
Return on average assets -35.41% -28.94%
Return on average equity - -
Employees 260 -
CDP Score - -

Address

2 Snunit St., Science Park, POB 455
KARMIEL, 20100
Israel
+972-4-9028100 (Phone)
+972-4-9889489 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Protalix BioTherapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its ProCellEx protein expression system, ProCellEx. Using its ProCellEx system, the Company is developing a pipeline of biosimilar or generic versions of recombinant therapeutic proteins based on its plant cell-based expression technology, which focuses pharmaceutical markets and that rely upon known biological mechanisms of action. ProCellEx protein expression system consists of a set of technologies and capabilities for the development of recombinant proteins, including advanced genetic engineering technology and plant cell-based protein expression methods. Its ProCellEx protein expression system is built on flexible custom-designed bioreactors made of polyethylene and optimized for the development of complex proteins in plant cell cultures. In June 2010, it had completed the preliminary phase I clinical trial of PRX-105.

Officers and directors

Shlomo Yanai Chairman of the Board
Age: 62
Bio & Compensation  - Reuters
Moshe Manor President, Chief Executive Officer
Age: 58
Bio & Compensation  - Reuters
Yossi Maimon CPA Chief Financial Officer, Vice President, Treasurer, Secretary
Age: 42
Bio & Compensation  - Reuters
Tzvi Palash Chief Operating Officer
Age: 56
Bio & Compensation  - Reuters
Yoseph Shaaltiel Executive Vice President - Research & Development, Director
Age: 59
Bio & Compensation  - Reuters
Einat Brill Almon Ph.D. Senior Vice President - Product Development
Age: 53
Bio & Compensation  - Reuters
Sandra L. Lauterbach Vice President - Sales and Commercial Affairs
Age: 44
Bio & Compensation  - Reuters
Zeev Bronfeld Director
Age: 63
Bio & Compensation  - Reuters
Amos Bar-Shalev Independent Director
Age: 60
Bio & Compensation  - Reuters
Yodfat Harel Gross Independent Director
Age: 41
Bio & Compensation  - Reuters